A Phase 1 trial for TTI-622 with dose escalation and expansion phase focused on combination treatment
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2017
At a glance
- Drugs TTI 622 (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Sponsors Trillium Therapeutics Inc
- 10 Nov 2017 According to a Trillium Therapeutics media release, IND will be submitted in the Fourth Quarter of 2017.
- 01 Jun 2017 According to a Trillium Therapeutics Inc. media release, an Investigational New Drug (IND) application for TTI-662 combination therapy is targeted for the second half of 2017.
- 01 Jun 2017 Indications are assumed based on RDI profile. Subjects are assumed as an adult patients and gender as male & female.